Table 1

Patient characteristics

Age, median (IQR) (SD)63 (51, 70)
Sex, male n (%)38 (63)
Cancer stage, n (%)
Stage III9 (15)
Stage IV51 (85)
Melanoma type, n (%)
Cutaneous37 (61.7)
Uveal1 (1.7)
Acral1 (1.7)
Mucosal16 (26.7)
Unknown5 (8.3)
Cycles of ICI received, median (IQR)5.5 (3, 18.5)
Total number of irAE, median (IQR)3(2, 5)
Max irAE grading, n (%)
None5 (8.3)
Mild (grade 1–2)27 (45)
Severe (grade 3–5)28 (46.7)
Timing to first irAE, n (%)
<6 weeks38 (63)
≥6 weeks17 (28)
Time to first severe irAE, n (%)
<6 weeks6 (21)
≥6 weeks22 (79)
ANA positivity, n (%)
Baseline14 (23.3)
6 weeks14 (23.3)
Any timepoint19 (31.7)
RF positivity, n (%)
Baseline4 (6.7)
6 weeks4 (6.7)
Any timepoint6 (10)
Anti-CCP positivity, n (%)
Baseline0
6 weeks1 (2)
Any timepoint1 (2)
RF, CCP or ANA positive at baseline, n (%)17 (28)
RF, CCP or ANA positive at any timepoint, n (%)24 (40)
  • ANA, antinuclear antibody; anti-CCP, anti-cyclic citrullinated peptide; ICI, immune checkpoint inhibitor; irAE, immune-related adverse event; RF, rheumatoid factor.